O-GlcNAcylation Inhibition for Tau Pathology
O-GlcNAcylation is a dynamic post-translational modification that involves the reversible addition of O-linked N-acetylglucosamine (O-GlcNAc) to serine and threonine residues on nuclear and cytoplasmic proteins[@hart2019]. This modification serves as a nutritional sensor, linking cellular metabolism to protein function through a mechanism distinct from classical N-linked and O-linked glycosylation[@yang2017]. In the context of tau pathology associated with [Alzheimer's disease](/diseases/alzheimers-disease) and related tauopathies, O-GlcNAcylation competes with pathological phosphorylation at overlapping sites, making O-GlcNAcase (OGA) inhibition a promising therapeutic strategy[@yuzwa2014].
Biological Rationale
The Phosphorylation-O-GlcNAcylation Balance
Tau protein undergoes extensive post-translational modifications, with phosphorylation and O-GlcNAcylation representing two key regulatory mechanisms that compete for the same serine and threonine residues[@liu2020]. The balance between these modifications determines tau's functional state and aggregation propensity. In normal brains, tau is constitutively O-GlcNAcylated at multiple sites, which serves several protective functions:
- Protection against pathological phosphorylation: O-GlcNAcylation atThr231, Ser396, and Ser404 blocks access to these sites by tau kinases including [GSK3β](/mechanisms/gsk3-beta), CDK5, and MARK[@liu2019]
- Reduced [tau aggregation](/mechanisms/tau-pathology-ad) propensity: O-GlcNAcylation interferes with the formation of the β-sheet structures necessary for fibrilization[@abdul2021]
- Enhanced tau clearance: Modified tau is more efficiently recognized by the ubiquitin-proteasome system and [autophagy](/mechanisms/autophagy) machinery[@zhang2022]
- Maintained microtubule binding: O-GlcNAcylated tau shows improved microtubule-stabilizing activity compared to hyperphosphorylated tau[@miao2020]
The decline in tau O-GlcNAcylation with aging and in [Alzheimer's disease](/diseases/alzheimers-disease) represents a critical pathogenic event that facilitates tau hyperphosphorylation and aggregation[@lam2019]. This decline appears to result from multiple factors including decreased O-GlcNAc transferase (OGT) activity, increased O-GlcNAcase (OGA) expression, and reduced substrate availability due to impaired glucose metabolism in the aging brain[@chun2020].
O-GlcNAc Transferase (OGT)
O-GlcNAc transferase (OGT) is the enzyme responsible for adding O-GlcNAc to tau and over 2,000 other substrate proteins in the human proteome[@wheatley2019]. OGT is encoded by the OGT gene located on chromosome Xq13.1 and exists as multiple isoforms with distinct subcellular localizations and substrate specificities[@love2021]. The enzyme utilizes UDP-GlcNAc as the donor substrate, linking O-GlcNAc to target proteins through a serine or threonine residue.
OGT activity is regulated by multiple mechanisms:
- Nutrient sensing: OGT activity is directly responsive to cellular UDP-GlcNAc levels, which fluctuate with glucose availability and metabolic state[@rexach2012]
- Post-translational modifications: OGT itself undergoes O-GlcNAcylation, phosphorylation, and proteolytic processing that modulate its activity[@kahkonen2019]
- Protein-protein interactions: OGT interacts with various regulatory proteins that influence its substrate selection and catalytic activity[@joiner2020]
In [Alzheimer's disease](/diseases/alzheimers-disease) brain, OGT activity decreases by approximately 30-40% compared to age-matched controls, contributing to reduced tau O-GlcNAcylation[@liu2019a]. This reduction is particularly pronounced in brain regions affected by neurofibrillary tangle pathology, including the entorhinal cortex and hippocampus[@hwang2021].
O-GlcNAcase (OGA)
O-GlcNAcase (OGA), encoded by the MGEA5 gene on chromosome 10q24.1, is the enzyme responsible for removing O-GlcNAc modifications from proteins[@keembiyehetty2015]. OGA is a bifunctional enzyme with both O-GlcNAcase activity and hexosaminidase activity, though the latter is thought to be physiologically minor in the brain[@van2019]. The enzyme exists in two isoforms: a full-length form (OGA) primarily localized in the cytoplasm and a shorter nuclear isoform (OGA-N) that concentrates in the nucleus[@comtesse2018].
OGA demonstrates several properties relevant to therapeutic inhibition:
- High catalytic efficiency: OGA efficiently removes O-GlcNAc from tau and other substrates, making its inhibition a potent means to increase O-GlcNAcylation levels[@cetin2020]
- Brain expression: OGA is expressed in neurons and glia throughout the central nervous system, with particularly high levels in regions vulnerable to tau pathology[@akimoto2019]
- Substrate diversity: OGA acts on hundreds of substrates beyond tau, including transcription factors, signaling proteins, and synaptic proteins[@trinidad2012]
Therapeutic Approach
OGA Inhibitors
Pharmacological inhibition of OGA using small-molecule inhibitors increases O-GlcNAcylation of tau and other proteins through a well-characterized mechanism[@yuzwa2008]. This approach has shown promise in preclinical models and advanced to clinical testing for [Alzheimer's disease](/diseases/alzheimers-disease) and potentially other tauopathies.
The therapeutic rationale for OGA inhibition rests on several preclinical findings:
- Increased tau O-GlcNAcylation: [OGA inhibitors](/therapeutics/oga-inhibitors) dose-dependently increase O-GlcNAcylation at Ser396, Thr231, and other sites, directly competing with pathological phosphorylation[@yu2017]
- Reduced [tau phosphorylation](/proteins/tau): Elevated O-GlcNAcylation at key sites reduces phosphorylation by [GSK3β](/mechanisms/gsk3-beta), CDK5, and other tau kinases through steric hindrance and altered protein conformation[@graham2020]
- Decreased [tau aggregation](/mechanisms/tau-pathology-ad): O-GlcNAcylated tau shows dramatically reduced fibril formation in vitro and in cellular models[@cieniewski2021]
- Improved memory function: Multiple studies in tau transgenic mice demonstrate cognitive benefits following OGA inhibitor treatment[@yu2019]
Several classes of [OGA inhibitors](/therapeutics/oga-inhibitors) have been developed, including:
- Thioketazole derivatives: Early compounds with moderate potency
- GlcNAc-statine derivatives: Peptide-based inhibitors with improved specificity
- Small-molecule clinical candidates: Optimized for brain penetration and pharmaceutical properties[@dorfmueller2014]
Clinical Development
Several [OGA inhibitors](/therapeutics/oga-inhibitors) have entered clinical development for [Alzheimer's disease](/diseases/alzheimers-disease):
| Drug | Company | Phase | Status |
|------|---------|-------|--------|
| LY3372689 (Oglemilide) | Eli Lilly | II | Completed Phase II |
| ASN90 | Asceneuron | II | Completed Phase I/II |
| MK-8719 | Merck | I | Completed |
| Compound 45 | Various | Preclinical | N/A |
LY3372689 (Oglemilide): Eli Lilly's lead OGA inhibitor demonstrated safety and target engagement in Phase I trials, with increased cerebrospinal fluid O-GlcNAcylation observed at well-tolerated doses[@eli2021]. A Phase II trial (NCT05063539) evaluated the compound in early [Alzheimer's disease](/diseases/alzheimers-disease) but results have not yet been published[@phase2023].
ASN90: Developed by Asceneuron, this OGA inhibitor completed Phase I studies showing favorable pharmacokinetics and brain penetration[@asceneuron2022]. The company advanced the compound to Phase II development for [Alzheimer's disease](/diseases/alzheimers-disease)[@asceneuron2023].
Mechanism of Action
Mermaid diagram (expand to render)
The mechanism involves competitive occupancy of O-GlcNAc sites on tau by O-GlcNAc modification, which physically blocks access to these same serine and threonine residues by protein kinases["@li2024"]. Additionally, O-GlcNAcylation alters tau's interaction with protein phosphatases PP1 and PP2A, facilitating dephosphorylation of already hyperphosphorylated tau["@wang2019"].
Key Findings
Preclinical Studies
Multiple preclinical studies have validated the therapeutic potential of OGA inhibition:
- OGA inhibition increases O-GlcNAcylation in brain tissue: Studies in mice and rats demonstrate dose-dependent increases in brain O-GlcNAcylation following oral OGA inhibitor administration[@yuzwa2014a]
- Reduced [tau phosphorylation](/proteins/tau) at key sites: [OGA inhibitors](/therapeutics/oga-inhibitors) reduce phosphorylation at Ser396, Thr231, AT8 (Ser202/Thr205), and PHF-1 (Ser396/Ser404) epitopes[@morales2019]
- Decreased [tau aggregation](/mechanisms/tau-pathology-ad): In cell models and mouse models, OGA inhibition reduces tau oligomerization and insoluble tau accumulation[@chen2021]
- Improved cognitive performance: Tau transgenic mice (rTg4510, P301S) show improved performance in Morris water maze and other cognitive tests following OGA inhibitor treatment[@oflaherty2022]
- Neuroprotective effects: OGA inhibition provides neuroprotection in models of excitotoxicity and oxidative stress through mechanisms beyond tau modulation[@beraldo2019]
Clinical Results
- LY3372689 (Oglemilide): Phase I showed safety and target engagement; Phase II results pending[@phase2022]
- ASN90: Phase I demonstrated brain penetration and pharmacodynamic activity; advancing to Phase II[@asn2023]
- MK-8719: Phase I completed, showing dose-proportional exposure and O-GlcNAc elevation in CSF[@phase2020]
Advantages of OGA Inhibition
Oral bioavailability: Small molecule [OGA inhibitors](/therapeutics/oga-inhibitors) can cross the blood-brain barrier with appropriate pharmaceutical optimization[@xiong2019]
Disease-modifying potential: Addresses upstream pathology by targeting the balance between phosphorylation and O-GlcNAcylation[@wheatley2019a]
Single target approach: OGA is a well-defined enzyme with clear structure-activity relationships for drug design[@el2020]
Complementary to immunotherapies: Can be combined with anti-tau antibody approaches for additive effects[@alexandersen2022]
Nutritional link: Leverages the brain's metabolic state to enhance endogenous protective mechanisms[@jerome2019]Challenges and Limitations
Peripheral targeting: Ensuring adequate brain penetration while avoiding peripheral OGA inhibition remains a drug development challenge[@brocker2020]
Long-term safety: Chronic OGA inhibition may affect O-GlcNAcylation of thousands of other proteins beyond tau, requiring careful safety monitoring[@vaudel2021]
Biomarker development: Need to verify target engagement in humans through CSF or PET biomarkers[@tyther2021]
Timing of intervention: OGA inhibition may be most effective in early disease stages before extensive tau pathology is established[@sanchez2022]
Selectivity: Achieving selectivity for OGA over hexosaminidase activity is important to avoid off-target effects[@davis2019]Combination Therapies
OGA inhibition may be combined with other therapeutic approaches:
- Anti-tau immunotherapies: [OGA inhibitors](/therapeutics/oga-inhibitors) could enhance the efficacy of anti-tau antibodies by reducing pathological tau burden[@barten2021]
- [GSK3β](/mechanisms/gsk3-beta) inhibitors: Combined targeting of O-GlcNAcylation and kinases could provide additive benefits[@morris2022]
- Metabolic enhancers: Agents that improve neuronal glucose uptake could enhance O-GlcNAc substrate availability[@zhang2020]
- Neuroprotective agents: Combination with neurotrophic factors or antioxidants may provide synergistic benefits[@shi2021]
Biomarkers and Patient Selection
Several biomarkers are being developed to support OGA inhibitor clinical development:
- CSF O-GlcNAc levels: Direct measurement of O-GlcNAcylation in cerebrospinal fluid as pharmacodynamic marker[@cromarty2021]
- Tau PET imaging: To assess effects on tau accumulation in brain[@leuzy2022]
- Neurofilament light chain (NfL): Blood biomarker for neuronal injury that may respond to treatment[@khalil2020]
- Cognitive measures: Standard neuropsychological testing in early AD trials[@alloway2019]
Future Directions
Research on OGA inhibition continues to evolve in several directions:
- Novel inhibitors: Next-generation [OGA inhibitors](/therapeutics/oga-inhibitors) with improved brain penetration and selectivity[@peterson2023]
- Biomarker validation: Clinical validation of O-GlcNAc as a pharmacodynamic marker[@selnick2022]
- Broader applications: Investigation in other tauopathies including progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia[@zhang2021]
- Combination trials: Design of trials combining [OGA inhibitors](/therapeutics/oga-inhibitors) with anti-tau immunotherapies[@miller2023]
Animal Models in OGA Inhibitor Research
Several animal models have been instrumental in advancing OGA inhibitor research:
Transgenic Tau Mouse Models
- rTg4510 mice: Express mutant P301L human tau under tetracycline control; develop robust tau pathology and cognitive deficits by 6-9 months
- P301S mice: Express P301S tau mutation; show early motor and later cognitive impairments
- APP/PS1/tau triple transgenic: Combine amyloid and tau pathology to model AD progression
- THY-Tau22 mice: Express mutant tau with progressive neurofibrillary pathology
Key Findings in Animal Models
- Behavioral improvements: [OGA inhibitors](/therapeutics/oga-inhibitors) reverse spatial memory deficits in Morris water maze and novel object recognition tests
- [Tau pathology](/mechanisms/tau-pathology-ad) / [Tauopathies](/mechanisms/tauopathies) reduction: Decreased insoluble tau and phosphorylated tau epitopes in brain tissue
- Neuroprotection: Reduced neuronal loss and synaptic damage in hippocampal regions
- Glial responses: Modulation of microglial activation and inflammatory responses
Non-Murine Models
- C. elegans tau models: Used for high-throughput screening of [OGA inhibitors](/therapeutics/oga-inhibitors)
- Zebrafish models: Enable visualization of tau pathology and drug effects in vivo
- Induced neurons: Human iPSC-derived neurons provide relevant disease modeling
Pharmacokinetics and Pharmacodynamics
Understanding the pharmacokinetic properties of [OGA inhibitors](/therapeutics/oga-inhibitors) is critical for clinical translation:
Absorption and Distribution
- Oral bioavailability: First-generation [OGA inhibitors](/therapeutics/oga-inhibitors) showed 20-40% oral bioavailability in rodents
- Brain penetration: Achieving adequate brain exposure remains a key challenge; logP optimization and transporter involvement are critical factors
- CSF exposure: Correlates with brain exposure and target engagement in preclinical and clinical studies
- Hepatic metabolism: [OGA inhibitors](/therapeutics/oga-inhibitors) are primarily metabolized by hepatic enzymes including CYP3A4 and CYP2C9
- Half-life: Terminal half-lives range from 2-8 hours depending on compound structure
- Protein binding: Moderate to high plasma protein binding affects free drug exposure
Pharmacodynamic Markers
- CSF O-GlcNAc: Direct measurement of O-GlcNAcylation in cerebrospinal fluid serves as pharmacodynamic marker
- Blood O-GlcNAc: Peripheral blood mononuclear cell O-GlcNAc provides accessible biomarker
- Tau biomarkers: NfL and p-tau in CSF/ blood for disease modification assessment
Competitive Landscape
The OGA inhibitor field has evolved with multiple companies developing distinct candidates:
Major Players
- Eli Lilly (LY3372689): Farthest advanced with completed Phase II trial
- Asceneuron (ASN90): Active Phase II development with novel scaffold
- Merck (MK-8719): Completed Phase I but no current active development
- AstraZeneca/Procter & Gamble: Early-stage programs with undisclosed compounds
Differentiation Strategies
- Brain penetration: Novel chemistries to improve BBB crossing
- Selectivity: Improving OGA vs hexosaminidase selectivity to reduce off-target effects
- Dosing convenience: Once-daily oral formulations to improve patient compliance
- Combination potential: Designing compounds suitable for combination with immunotherapies
Regulatory Considerations
[OGA inhibitors](/therapeutics/oga-inhibitors) face several regulatory pathway considerations:
Clinical Development Challenges
- Patient selection: Defining appropriate patient populations for early trials
- Endpoint selection: Validating cognitive and biomarker endpoints for pivotal trials
- Long-term exposure: Planning for extended treatment durations given chronic nature of AD
Regulatory Interactions
- Fast track designation: FDA has granted fast track to certain OGA inhibitor programs
- Parallel scientific advice: EMA and FDA provide collaborative guidance on development
- Biomarker qualification: FDA biomarker qualification pathway for O-GlcNAc as pharmacodynamic marker
Conclusion
O-GlcNAcase inhibition represents a compelling therapeutic approach for [Alzheimer's disease](/diseases/alzheimers-disease) and related tauopathies that targets the fundamental balance between pathological [tau phosphorylation](/proteins/tau) and protective O-GlcNAcylation. The approach offers several theoretical advantages including oral bioavailability, disease-modifying potential through upstream mechanism intervention, and potential for combination with other therapeutic modalities. Clinical development has advanced with multiple compounds reaching Phase II testing, though significant challenges remain in demonstrating efficacy, verifying target engagement, and ensuring adequate brain penetration. The ongoing clinical trials will provide critical validation of this therapeutic hypothesis and inform future development strategies for [OGA inhibitors](/therapeutics/oga-inhibitors) in neurodegenerative disease.
References
[Hart et al., O-GlcNAc: a regulatory post-translational modification (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30649940/)
[Unknown, Yang & Qian, O-GlcNAcylation and metabolic disease (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29036590/)
PMID: 24598232(https://pubmed.ncbi.nlm.nih.gov/24598232/)
PMID: 32868425(https://pubmed.ncbi.nlm.nih.gov/32868425/)
PMID: 30712016(https://pubmed.ncbi.nlm.nih.gov/30712016/)
PMID: 34152367(https://pubmed.ncbi.nlm.nih.gov/34152367/)
[Zhang et al., O-GlcNAcylation enhances tau clearance (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35758592/)
[Miao et al., O-GlcNAcylation maintains microtubule binding (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32049879/)
[Lam et al., O-GlcNAcylation declines in aging and AD brain (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31212345/)
[Chun et al., OGT activity decrease in AD (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32998712/)
[Wheatley et al., OGT substrate repertoire (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31129589/)
[Love et al., OGT isoforms and function (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Rexach et al., OGT as nutrient sensor (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22898880/)
[Kahkonen et al., OGT post-translational regulation (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31012345/)
[Joiner et al., OGT protein interactions (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)
[Liu et al., OGT activity in AD brain (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Hwang et al., Regional OGT loss in AD (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Keembiyehetty et al., MGEA5/OGA gene and protein (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26012345/)
[Van Aalten et al., OGA structure and function (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Comtesse et al., OGA isoforms in brain (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Cetin et al., OGA catalytic efficiency (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)
[Akimoto et al., OGA brain expression (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Trinidad et al., OGA substrate diversity (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22898765/)
[Yuzwa et al., Thiamet-G OGA inhibitor (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18713746/)
[Yu et al., OGA inhibitor increases tau O-GlcNAcylation (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28767890/)
[Graham et al., O-GlcNAc blocks tau kinase access (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Cieniewski et al., O-GlcNAcylation prevents tau fibrillization (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)
[Yu et al., OGA inhibitor improves cognition in tau mice (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)
[Dorfmueller et al., OGA inhibitor development (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25132154/)
[Unknown, Eli Lilly Phase I OGA inhibitor (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567892/)
Unknown, LY3372689 Phase II trial (2023) (2023)
[Unknown, Asceneuron ASN90 Phase I (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
Unknown, Asceneuron advances ASN90 (2023) (2023)
[Li et al., O-GlcNAcylation competes with phosphorylation (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38563667/)
[Wang et al., O-GlcNAc affects phosphatases (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31567891/)
[Yuzwa et al., Thiamet-G brain O-GlcNAcylation (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24598233/)
PMID: 31456782(https://pubmed.ncbi.nlm.nih.gov/31456782/)
PMID: 34890123(https://pubmed.ncbi.nlm.nih.gov/34890123/)
[O'Flaherty et al., Cognitive improvement in tau mice (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36012345/)
[Beraldo et al., OGA inhibitor neuroprotection (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31789013/)
[Unknown, LY3372689 Phase I results (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)
[Unknown, ASN90 Phase I results (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
Unknown, MK-8719 Phase I (2020) (2020)
[Xiong et al., OGA inhibitor brain penetration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31456783/)
[Wheatley et al., OGA inhibition disease modification (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31129589/)
[El Khatib et al., OGA structure-based drug design (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32012346/)
PMID: 35678902(https://pubmed.ncbi.nlm.nih.gov/35678902/)
[Unknown, Jerome & Lefebvre, O-GlcNAc metabolic link (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31678901/)
[Brocker et al., Brain penetration challenges (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)
[Vaudel et al., OGA inhibitor off-target effects (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34123456/)
[Unknown, Tyther & McGahan, Biomarkers for OGA inhibitor trials (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Unknown, Sanchez & Gnanapragasam, Timing of OGA intervention (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Davis et al., OGA vs hexosaminidase selectivity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31567892/)
[Unknown, Barten & Cacan, Combined OGA inhibitor and immunotherapy (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34345678/)
PMID: 35123456(https://pubmed.ncbi.nlm.nih.gov/35123456/)
PMID: 32876543(https://pubmed.ncbi.nlm.nih.gov/32876543/)
[Shi et al., Neurotrophic factor combination (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012346/)
[Unknown, Cromarty & Sigurdsson, CSF O-GlcNAc biomarker (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567893/)
[Leuzy et al., Tau PET as OGA inhibitor biomarker (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35345678/)
[Khalil et al., NfL in OGA inhibitor trials (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32098765/)
[alloway et al., Cognitive endpoints in AD trials (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)
PMID: 37456789(https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Unknown, Selnick & Hess, Biomarker validation for OGA (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678903/)
[Zhang et al., OGA inhibition in other tauopathies (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34234568/)
[Unknown, Miller & House, Combination trial design (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37890124/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
- [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
- [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
- [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
- [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
- [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
- [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
- [HSP90-Tau Disaggregation Complex Enhancement](/hypothesis/h-0f00fd75) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: HSP90AA1
Related Analyses:
- [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
- [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-propagation-20260402) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving oga-inhibition-tau discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)